Literature DB >> 17926946

Out-of-field dose equivalents delivered by proton therapy of prostate cancer.

Andrew Wroe1, Anatoly Rosenfeld, Reinhard Schulte.   

Abstract

Measurements were performed to assess the dose equivalent outside a primary proton treatment field, using a silicon-on-insulator (SOI) microdosimeter. The SOI microdosimeter was placed on the surface of an anthropomorphic phantom and dose equivalents were determined as a function of lateral distance from a typical passively scattered and modulated prostate treatment field. Measurements were also completed within a polystyrene plate phantom as a function of depth for a distance of 5 cm from the field edge, as function of lateral distance from field edge at two different depths, and as a function of distance from the distal edge on the central beam axis. The dose equivalent at the surface of the anthropomorphic phantom decreases from 3.9 to 0.18 mSv/Gy when the lateral distance from the proton field edge increases from 2.5 to 60 cm. Measurements along the proton depth dose distribution at a constant distance of 5 cm from the primary field edge indicate a decrease in dose equivalent as a function of depth, with a 38% decrease relative to the surface dose at a depth of 5 cm in polystyrene. Measurements completed as a function of lateral distance from the primary field at two separate depths within polystyrene illustrate a convergence of the dose equivalent at approximately 20 cm from the primary field edge. Past the distal edge of the spread-out Bragg peak dose equivalents decrease exponentially for increasing distance, with an initial value of 1.6 mSv/Gy at 0.6 cm from the distal edge. Silicon microdosimetry measurements were also compared with published results obtained utilizing different measurement techniques. This study demonstrates the applicability of SOI microdosimetry in determining the dose equivalent outside proton treatment fields, and provides valuable information on the dose equivalent both at the surface and at depth experienced by prostate cancer patients treated with protons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17926946     DOI: 10.1118/1.2759839

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  20 in total

1.  An analytic model of neutron ambient dose equivalent and equivalent dose for proton radiotherapy.

Authors:  Rui Zhang; Angélica Pérez-Andújar; Jonas D Fontenot; Phillip J Taddei; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  Assessment of out-of-field absorbed dose and equivalent dose in proton fields.

Authors:  Ben Clasie; Andrew Wroe; Hanne Kooy; Nicolas Depauw; Jay Flanz; Harald Paganetti; Anatoly Rosenfeld
Journal:  Med Phys       Date:  2010-01       Impact factor: 4.071

3.  Monte Carlo and analytical model predictions of leakage neutron exposures from passively scattered proton therapy.

Authors:  Angélica Pérez-Andújar; Rui Zhang; Wayne Newhauser
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

4.  Comment on "Proton beam and prostate cancer: An evolving debate" by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338-42].

Authors:  Carl J Rossi
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-15

Review 5.  Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy.

Authors:  Harald Paganetti
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

6.  ANALYTICAL MODEL TO ESTIMATE EQUIVALENT DOSE FROM INTERNAL NEUTRONS IN PROTON THERAPY OF CHILDREN WITH INTRACRANIAL TUMORS.

Authors:  Kyle J Gallagher; Phillip J Taddei
Journal:  Radiat Prot Dosimetry       Date:  2019-06-01       Impact factor: 0.972

7.  Reduction of the secondary neutron dose in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator.

Authors:  David J Brenner; Carl D Elliston; Eric J Hall; Harald Paganetti
Journal:  Phys Med Biol       Date:  2009-09-24       Impact factor: 3.609

8.  Monte Carlo simulation of the neutron spectral fluence and dose equivalent for use in shielding a proton therapy vault.

Authors:  Yuanshui Zheng; Wayne Newhauser; Eric Klein; Daniel Low
Journal:  Phys Med Biol       Date:  2009-11-04       Impact factor: 3.609

Review 9.  Clinical controversies: proton therapy for prostate cancer.

Authors:  Kent W Mouw; Alexei Trofimov; Anthony L Zietman; Jason A Efstathiou
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

Review 10.  Is there a place for quantitative risk assessment?

Authors:  Eric J Hall
Journal:  J Radiol Prot       Date:  2009-05-19       Impact factor: 1.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.